• Intranasal Vaccines, Vax Data for RWD Exploration, Down Syndrome Impacts: COVID-19 Updates

    Clinical Research News | A survey of how rehabilitation is helping patients with severe COVID-19, what COVID-19 means for Down Syndrome patients, and the timing of vaccines. Plus: real world data for COVID-19 vaccination, intranasal COVID-19 vaccine, more.

    Feb 26, 2021

  • It Took A Village To Speed Pfizer COVID-19 Vaccine Into Arms

    Clinical Research News | Deployment of clinical trials for Pfizer’s COVID-19 vaccine candidate was the fastest in the company’s history, and possibly industry-wide. Six weeks after the decision was made to run the combined phase 1/2/3 study, the first patient was enrolled and, six months later, it had all the safety and efficacy data needed to request Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to start getting the vaccine into people’s arms.

    Feb 25, 2021

  • Adaptive Trial Design Takes Center Stage During Pandemic

    Clinical Research News | The pandemic has had some “silver linings” for clinical studies and the overall U.S. healthcare system, according to speakers discussing adaptive trial design at the recent COVID-19 and Cancer virtual meeting of the American Association for Cancer Research (AACR). We can’t go back to business as usual.

    Feb 23, 2021

  • PTSD, Lasting Heart Damage, Brain Findings: Lasting Impacts for COVID-19 Patients

    Clinical Research News | Europe’s vaccination priority for the mentally ill, fighting “vaccine nationalism”, how the humidity inside the face mask can help. Plus: trials of remdesivir in pregnant women, EMA releases guidance on trials during pandemic, and seeking priority vaccines for cancer patients, diabetes sufferers.

    Feb 19, 2021

  • GSK’s Protocol Design Lab Offers Actionable Insights To Study Teams

    Clinical Research News | A Protocol Design Lab (PDL) launched by GlaxoSmithKline (GSK) at the end of 2019 is endeavoring to harness insights from real-world data, clinical trials, and patients themselves to create “operationally viable” protocols linked to predetermined value drivers—notably, clinical studies that are faster and less costly to conduct and include a greater diversity of patients.

    Feb 18, 2021